Rebecca L. Olin, MD

Amherst College, Amherst, MA, B.A., 1999, Biology
University of Pennsylvania School of Medicine, M.D., 2003
University of Pennsylvania, M.S., 2009, Clinical Epidemiology

• 2003-2006
  Internship and residency, Internal Medicine, University of Pennsylvania Hospital
• 2006-2009
  Fellowship, Hematology/Oncology, University of Pennsylvania Hospital
• 2007-2008
  Chief Fellow, Hematology/Oncology, University of Pennsylvania Hospital
• 2009-present
  Assistant Clinical Professor of Medicine, University of California San Francisco

• 1999
  Phi Beta Kappa, Amherst College
• 2002
  Alpha Omega Alpha, early induction, University of Pennsylvania
• 2002
  Botelho Prize for Excellence in Basic Science
• 2003
  Dr. Spencer Morris Prize
• 2005
  American Society of Hematology Trainee Award
• 2008
  American Society of Hematology Travel Award

• Olin RL, Desai SS, Fox K, Davidson R. Non-Myopathic Cardiac Events in Two Patients Treated with Trastuzumab. The Breast Journal. 2007 Mar-Apr;13(2):211-2.
• Olin RL, Nichols KE, Naghashpour M, Wasik M, Shelly B, Stadtmauer EA, Vogl DT. Successful treatment of hemophagocytic lymphohistiocytosis with the anti-CD25 antibody daclizumab. American Journal of Hematology. 2008 Sep;83(9):747-9.
• Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA. Second autologous stem cell transplant (ASCT) is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplantation. 2009 Mar;43(5):417-22.